Encorium Reports (Nasdaq: ENCO)Third Quarter 2009 Financial Results

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the third quarter ended September 30, 2009.

Free Hot Penny Stocks, an online financial publication, provides investors timely stock market alerts. Free hot penny stocks profiles stock picks that could generate higher returns than average. These penny stocks include stocks with news, chart breakouts or increased volume.

Sign Up Today for our Penny Stock Newsletter

Net revenue for the third quarter of 2009 was $4.5 million, a decrease of 17.6% from $5.4 million for the third quarter of 2008. The decrease in net revenues was primarily attributable to unfavorable foreign currency fluctuations of $200,000 for the three months ended September 30, 2009. Approximately $650,000 was attributable to revenue recognized on a contract that completed in 2008. The Company had a consolidated backlog at September 30, 2009 from continuing operations of $19.9 million which included approximately $8.3 million of new business wins in the first nine months of 2009 compared to a backlog of $27.0 million at September 30, 2008.  As previously announced, on July 16, 2009 the Company sold substantially all of the assets relating to its US line of business to Pierrel Research USA, Inc., the result of which the Company no longer has any employees or significant operations in the United States. Due to this sale, for the three and nine months ended September 30, 2009 and 2008, the results of the U.S. business have been presented as discontinued operations in the Company's consolidated financial statements. Dr. Kai Lindevall, executive chairman stated, "We are very pleased that we were recently able to shore up our balance sheet. While additional financing is likely necessary, we believe our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning."

Sign Up for Free Hot Penny Stocks’ FREE Penny Stock Newsletter.

About Us

Free Hot Penny Stocks is a financial website and independent electronic publication that provides information and free penny stock alerts on selected publicly traded companies. We also track small cap companies and other stocks that may be positioned to break out. These penny stocks might have news, increased volume or chart breakouts. These penny stocks that are alerted could generate greater than average returns. Feel free to visit our penny stock forum to discuss other penny stock picks or penny stocks that you might own.

Free Hot Penny Stocks is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer